<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26478609</article-id><article-id pub-id-type="pmc">4581657</article-id><article-id pub-id-type="publisher-id">BLT.14.147892</article-id><article-id pub-id-type="doi">10.2471/BLT.14.147892</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Nouveaux indicateurs pour mesurer le retard dans l&#x02019;acc&#x000e8;s au traitement antir&#x000e9;troviral: estimations pour le Cameroun</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Nuevos indicadores de retraso en el inicio del tratamiento antirretroviral: estimaciones para Camer&#x000fa;n</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00645;&#x00624;&#x00634;&#x00631;&#x00627;&#x0062a; &#x0062c;&#x0062f;&#x0064a;&#x0062f;&#x00629; &#x0062f;&#x00627;&#x00644;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062e;&#x00631; &#x00641;&#x0064a; &#x00628;&#x0062f;&#x00621; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629;: &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a;&#x000a0;&#x00627;&#x00644;&#x0062e;&#x00627;&#x00635;&#x00629;&#x000a0;&#x00628;&#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x0064a;&#x00631;&#x00648;&#x00646; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x06cbb;&#x07597;&#x07684;&#x05f00;&#x059cb;&#x065f6;&#x095f4;&#x05ef6;&#x08fdf;&#x07684;&#x065b0;&#x06307;&#x06807;&#x0ff1a; &#x05580;&#x09ea6;&#x09686;&#x05883;&#x05185;&#x07684;&#x04f30;&#x08ba1;&#x0503c;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0041d;&#x0043e;&#x00432;&#x0044b;&#x00435; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00438; &#x00437;&#x00430;&#x00434;&#x00435;&#x00440;&#x00436;&#x0043a;&#x00438; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x0043e;&#x00439; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x00438;: &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x00434;&#x0043b;&#x0044f; &#x0041a;&#x00430;&#x0043c;&#x00435;&#x00440;&#x00443;&#x0043d;&#x00430;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Jacques DA Ndawinz et al.</alt-title><alt-title alt-title-type="title-running-head">Delay in starting antiretrovirals, Cameroon</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ndawinz</surname><given-names>Jacques DA</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Anglaret</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Delaporte</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Koulla-Shiro</surname><given-names>Sinata</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gabillard</surname><given-names>Delphine</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Minga</surname><given-names>Albert</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Costagliola</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Supervie</surname><given-names>Virginie</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label>INSERM, Sorbonne Universit&#x000e9;s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d&#x02019;Epid&#x000e9;miologie et de Sant&#x000e9; Publique, F-75013, Paris, <country>France</country>.</aff><aff id="aff2"><label>b</label>INSERM, Universit&#x000e9; Bordeaux, Bordeaux, <country>France</country>.</aff><aff id="aff3"><label>c</label>IRD, Universit&#x000e9; de Montpellier 1, Montpellier, <country>France</country>.</aff><aff id="aff4"><label>d</label>Faculty of Medicine and Biomedical Sciences, University of Yaound&#x000e9;, Yaound&#x000e9;, <country>Cameroon</country>.</aff><aff id="aff5"><label>e</label>Programme PACCI, Abidjan, <country>C&#x000f4;te d&#x02019;Ivoire</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Virginie Supervie (email: virginie.<email xlink:href="supervie@inserm.fr">supervie@inserm.fr</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>01</day><month>6</month><year>2015</year></pub-date><volume>93</volume><issue>8</issue><fpage>521</fpage><lpage>528</lpage><history><date date-type="received"><day>24</day><month>9</month><year>2014</year></date><date date-type="rev-recd"><day>09</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>(c) 2015 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To propose two new indicators for monitoring access to antiretroviral treatment (ART) for human immunodeficiency virus (HIV); (i)&#x000a0;the time from HIV seroconversion to ART initiation, and (ii)&#x000a0;the time from ART eligibility to initiation, referred to as delay in ART initiation. To estimate values of these indicators in Cameroon.</p></sec><sec><title>Methods</title><p>We used linear regression to model the natural decline in CD4+ T-lymphocyte (CD4+ cell) numbers in HIV-infected individuals over time. The model was fitted using data from a cohort of 351 people in C&#x000f4;te d&#x02019;Ivoire. We used the model to estimate the time from seroconversion to ART initiation and the delay in ART initiation in a representative sample of 4154 HIV-infected people who started ART in Cameroon between 2007 and 2010.</p></sec><sec><title>Findings</title><p>In Cameroon, the median CD4+ cell counts at ART initiation increased from 140 cells/&#x003bc;l (interquartile range, IQR: 66 to 210) in 2007&#x02013;2009 to 163 cells/&#x003bc;l (IQR: 73 to 260) in 2010. The estimated average time from seroconversion to ART initiation decreased from 10.4&#x000a0;years (95% confidence interval, CI: 10.3 to 10.5) to 9.8&#x000a0;years (95% CI: 9.6 to 10.0). Delay in ART initiation increased from 3.4&#x000a0;years (95% CI: 3.1 to 3.7) to 5.8&#x000a0;years (95% CI: 5.6 to 6.2).</p></sec><sec><title>Conclusion</title><p>The estimated time to initiate ART and the delay in ART initiation indicate that progress in Cameroon is insufficient. These indicators should help monitor whether public health interventions to accelerate ART initiation are successful.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Proposer deux nouveaux indicateurs pour &#x000e9;valuer l'acc&#x000e8;s au traitement antir&#x000e9;troviral (TAR) contre le virus de l'immunod&#x000e9;ficience humaine (VIH): (i) le d&#x000e9;lai entre la s&#x000e9;roconversion au VIH et le d&#x000e9;but du TAR, et (ii) le d&#x000e9;lai entre l'&#x000e9;ligibilit&#x000e9; au TAR et le d&#x000e9;but du TAR, appel&#x000e9; &#x000ab;d&#x000e9;lai &#x000e9;coul&#x000e9; avant le d&#x000e9;but du TAR&#x000bb;. Estimer l'utilit&#x000e9; de ces indicateurs au Cameroun.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons utilis&#x000e9; une r&#x000e9;gression lin&#x000e9;aire pour mod&#x000e9;liser le d&#x000e9;clin naturel au fil du temps du nombre de lymphocytes T&#x000a0;CD4+ (cellule CD4+) chez les individus infect&#x000e9;s par le VIH. Le mod&#x000e8;le a &#x000e9;t&#x000e9; con&#x000e7;u &#x000e0; l'aide de donn&#x000e9;es provenant d'une cohorte de 351&#x000a0;individus de C&#x000f4;te d'Ivoire. Nous l'avons utilis&#x000e9; pour estimer le d&#x000e9;lai entre la s&#x000e9;roconversion et le d&#x000e9;but du TAR ainsi que le retard dans l&#x02019;acc&#x000e8;s au TAR sur un &#x000e9;chantillon repr&#x000e9;sentatif de 4154&#x000a0;individus infect&#x000e9;s par le VIH ayant commenc&#x000e9; un TAR au Cameroun entre 2007&#x000a0;et 2010.</p></sec><sec><title>R&#x000e9;sultats</title><p>Au Cameroun, le taux m&#x000e9;dian de CD4+ au d&#x000e9;but du TAR est pass&#x000e9; de 140&#x000a0;cellules 140&#x000a0;cellules/&#x003bc;l (intervalle interquartile, IQR: de 66&#x000a0;&#x000e0; 210)&#x000a0;en 2007&#x02013;2009&#x000a0;&#x000e0; 163&#x000a0;cellules/&#x003bc;l (IQR: de 73&#x000a0;&#x000e0; 260)&#x000a0;en 2010.&#x000a0;Le d&#x000e9;lai moyen estim&#x000e9; entre la s&#x000e9;roconversion et le d&#x000e9;but du TAR est pass&#x000e9; de 10,4&#x000a0;ann&#x000e9;es (intervalle de confiance, IC, &#x000e0; 95%:&#x000a0;de 10,3&#x000a0;&#x000e0; 10,5)&#x000a0;&#x000e0; 9,8&#x000a0;ann&#x000e9;es (IC &#x000e0; 95%:&#x000a0;de 9,6&#x000a0;&#x000e0; 10,0).&#x000a0;Le retard dans l&#x02019; acc&#x000e8;s au TAR est pass&#x000e9; de 3,4&#x000a0;ann&#x000e9;es (IC &#x000e0; 95%:&#x000a0;de 3,1&#x000a0;&#x000e0; 3,7)&#x000a0;&#x000e0; 5,8&#x000a0;ann&#x000e9;es (IC &#x000e0; 95%:&#x000a0;de 5,6&#x000a0;&#x000e0; 6,2).</p></sec><sec><title>Conclusion</title><p>Les estimations du d&#x000e9;lai entre la s&#x000e9;roconversion et le d&#x000e9;but du TAR et du retard dans l&#x02019;acc&#x000e8;s au TAR indiquent que les progr&#x000e8;s accomplis au Cameroun sont insuffisants. Ces indicateurs devraient aider &#x000e0; &#x000e9;valuer l'efficacit&#x000e9; des interventions de sant&#x000e9; publique visant &#x000e0; acc&#x000e9;l&#x000e9;rer l&#x02019;acc&#x000e8;s au TAR&#x000a0;.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Proponer dos nuevos indicadores para monitorear el acceso al tratamiento antirretroviral (TAR) para el virus de la inmunodeficiencia humana (VIH); (i) el tiempo desde la seroconversi&#x000f3;n del VIH al inicio del TAR, y (ii) el tiempo desde la elegibilidad del TAR al inicio del mismo, referido como retraso en el inicio del TAR. Estimar los valores de estos indicadores en Camer&#x000fa;n.</p></sec><sec><title>M&#x000e9;todos</title><p>Se utiliz&#x000f3; la regresi&#x000f3;n lineal para modelizar la disminuci&#x000f3;n natural de la cantidad de linfocitos T CD4+ (c&#x000e9;lula CD4+) en los individuos infectados por el VIH con el tiempo. El modelo se adapt&#x000f3; utilizando datos de una cohorte de 351 individuos en C&#x000f4;te d&#x02019;Ivoire. Se utiliz&#x000f3; el modelo para estimar el tiempo entre la seroconversi&#x000f3;n y el inicio del TAR y el retraso en el inicio del TAR en una muestra representativa de 4.154 individuos infectados por el VIH que iniciaron el TAR en Camer&#x000fa;n entre 2007 y 2010.</p></sec><sec><title>Resultados</title><p>En Camer&#x000fa;n, la media del recuento de c&#x000e9;lulas CD4+ en el inicio del TAR creci&#x000f3; de 140 c&#x000e9;lulas/&#x003bc;l (rango intercuart&#x000ed;lico, RIC: de 66 a 210) en 2007-2009 a 163 c&#x000e9;lulas/&#x003bc;l (RIC: de 73 a 260) en 2010. El tiempo medio estimado desde la seroconversi&#x000f3;n hasta el inicio del TAR descendi&#x000f3; de 10,4 a&#x000f1;os (intervalo de confianza, IC, del 95%: de 10,3 a 10,5) a 9,8 a&#x000f1;os (IC del 95%: de 9,6 a 10,0). El retraso en el inicio del TAR aument&#x000f3; de 3,4 a&#x000f1;os (IC del 95%: de 3,1 a 3,7) a 5,8 a&#x000f1;os (IC del 95%: de 5,6 a 6,2).</p></sec><sec><title>Conclusi&#x000f3;n</title><p>El tiempo estimado para iniciar el TAR y el retraso en el inicio del TAR indican que el progreso en Camer&#x000fa;n es insuficiente. Estos indicadores deber&#x000ed;an ayudar a monitorizar si las intervenciones de salud p&#x000fa;blica para acelerar el inicio del TAR son eficaces.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00627;&#x00642;&#x0062a;&#x00631;&#x00627;&#x0062d; &#x00645;&#x00624;&#x00634;&#x00631;&#x00627;&#x0062a; &#x0062c;&#x0062f;&#x0064a;&#x0062f;&#x00629; &#x00644;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x00649; &#x00639;&#x00644;&#x00627;&#x0062c; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629; (ART) &#x00644;&#x00645;&#x00642;&#x00627;&#x00648;&#x00645;&#x00629; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; (HIV)&#x0061b; (1) &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00627;&#x00644;&#x00632;&#x00645;&#x00646;&#x0064a;&#x00629; &#x00645;&#x00646;&#x00630; &#x00627;&#x00646;&#x00642;&#x00644;&#x00627;&#x00628; &#x0062a;&#x00641;&#x00627;&#x00639;&#x00644;&#x0064a;&#x00629; &#x00645;&#x00635;&#x00644; HIV (&#x00638;&#x00647;&#x00648;&#x00631; &#x00623;&#x0062c;&#x00633;&#x00627;&#x00645; &#x00645;&#x00636;&#x00627;&#x0062f;&#x00629; &#x00644;&#x00647;) &#x0062d;&#x0062a;&#x00649; &#x00628;&#x0062f;&#x00621; ART&#x0060c; &#x00648;(2) &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00627;&#x00644;&#x00632;&#x00645;&#x00646;&#x0064a;&#x00629; &#x00645;&#x00646;&#x00630; &#x00627;&#x00644;&#x0062a;&#x00623;&#x00647;&#x00644; &#x00644;&#x00640; ART &#x0062d;&#x0062a;&#x00649; &#x00627;&#x00644;&#x00628;&#x0062f;&#x00621; &#x00641;&#x0064a;&#x00647;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631; &#x00625;&#x00644;&#x0064a;&#x00647; &#x00628;&#x00627;&#x00644;&#x0062a;&#x00623;&#x0062e;&#x00631; &#x00641;&#x0064a; &#x00628;&#x0062f;&#x00621;ART . &#x00648;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00642;&#x0064a;&#x00645; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00635;&#x00644; &#x00625;&#x00644;&#x0064a;&#x00647;&#x00627; &#x00628;&#x00641;&#x00636;&#x00644; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00645;&#x00624;&#x00634;&#x00631;&#x00627;&#x0062a; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x0064a;&#x00631;&#x00648;&#x00646;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p> &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x00646;&#x00627; &#x00623;&#x00633;&#x00644;&#x00648;&#x00628; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00648;&#x00641; &#x00627;&#x00644;&#x0062e;&#x00637;&#x0064a; &#x00644;&#x00644;&#x00648;&#x00635;&#x00648;&#x00644; &#x00625;&#x00644;&#x00649; &#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00644;&#x00644;&#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00639;&#x0064a; &#x00641;&#x0064a; &#x00623;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00627;&#x00644;&#x00644;&#x00645;&#x00641;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00645;&#x00646; &#x00641;&#x00626;&#x00629; CD4+ (&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+ ) &#x00641;&#x0064a; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00645;&#x00631;&#x00636; &#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; &#x00645;&#x00639; &#x00645;&#x00631;&#x00648;&#x00631; &#x00627;&#x00644;&#x00648;&#x00642;&#x0062a;. &#x00648;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00645;&#x00646;&#x00627;&#x00633;&#x00628;&#x0064b;&#x00627; &#x00644;&#x00644;&#x0063a;&#x00631;&#x00636; &#x00628;&#x00641;&#x00636;&#x00644; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x0062a;&#x00645; &#x00627;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x0064a;&#x00647;&#x00627; &#x00645;&#x00646; &#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x0064a;&#x00628;&#x00644;&#x0063a; &#x00639;&#x0062f;&#x0062f;&#x00647;&#x00645; 351&#x000a0;&#x00634;&#x0062e;&#x00635;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x00643;&#x00648;&#x0062a;&#x000a0;&#x0062f;&#x0064a;&#x00641;&#x00648;&#x00627;&#x00631;. &#x00648;&#x00642;&#x0062f; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x00646;&#x00627; &#x00647;&#x00630;&#x00627; &#x00627;&#x00644;&#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00646;&#x00642;&#x00644;&#x00627;&#x00628; &#x0062a;&#x00641;&#x00627;&#x00639;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00635;&#x00644; &#x00648;&#x00628;&#x0062f;&#x00621;ART &#x00645;&#x00646; &#x00646;&#x00627;&#x0062d;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00641;&#x0062a;&#x00631;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062e;&#x00631; &#x00641;&#x0064a; &#x00628;&#x0062f;&#x00621;&#x000a0;ART &#x00645;&#x00646; &#x00646;&#x00627;&#x0062d;&#x0064a;&#x00629; &#x00623;&#x0062e;&#x00631;&#x00649;&#x0060c; &#x00648;&#x00630;&#x00644;&#x00643; &#x00641;&#x0064a; &#x00639;&#x0064a;&#x00646;&#x00629; &#x0062a;&#x00645;&#x0062b;&#x00644; &#x00627;&#x00644;&#x00645;&#x00631;&#x00636;&#x00649; &#x0062a;&#x00634;&#x00645;&#x00644; 4154&#x000a0;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064b;&#x00627; &#x00645;&#x00645;&#x00646; &#x00628;&#x0062f;&#x00623;&#x00648;&#x00627;ART &#x000a0;&#x00641;&#x0064a; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x0064a;&#x00631;&#x00648;&#x00646; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00628;&#x0064a;&#x00646; 2007&#x000a0;&#x00648;2010. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00632;&#x00627;&#x0062f; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x0064a;&#x00631;&#x00648;&#x00646; &#x00648;&#x00633;&#x0064a;&#x00637; &#x00627;&#x00644;&#x00642;&#x0064a;&#x00645;&#x00629; &#x00644;&#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+ &#x00639;&#x00646;&#x0062f; &#x00628;&#x0062f;&#x00621; ART &#x00645;&#x00646; 140 &#x0062e;&#x00644;&#x0064a;&#x00629;/&#x00645;&#x0064a;&#x00643;&#x00631;&#x00648; &#x00644;&#x0062a;&#x00631; (&#x00627;&#x00644;&#x00645;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00631;&#x00628;&#x0064a;&#x00639;&#x0064a;: 66 &#x00625;&#x00644;&#x00649; 210) &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00645;&#x00646; 2007&#x000a0;&#x02013;&#x000a0;2009 &#x00625;&#x00644;&#x00649; 163&#x000a0;&#x0062e;&#x00644;&#x0064a;&#x00629;/&#x00645;&#x0064a;&#x00643;&#x00631;&#x00648; &#x00644;&#x0062a;&#x00631; (&#x00627;&#x00644;&#x00645;&#x0062f;&#x00649;&#x000a0;&#x00627;&#x00644;&#x00631;&#x00628;&#x0064a;&#x00639;&#x0064a;: 73 &#x00625;&#x00644;&#x00649; 260) &#x00641;&#x0064a; &#x00639;&#x00627;&#x00645; 2010. &#x00648;&#x00627;&#x00646;&#x0062e;&#x00641;&#x00636; &#x00645;&#x0062a;&#x00648;&#x00633;&#x00637; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00627;&#x00644;&#x00632;&#x00645;&#x00646;&#x0064a;&#x00629; &#x00645;&#x00646;&#x00630; &#x00627;&#x00646;&#x00642;&#x00644;&#x00627;&#x00628; &#x0062a;&#x00641;&#x00627;&#x00639;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00635;&#x00644; &#x0062d;&#x0062a;&#x00649; &#x00628;&#x0062f;&#x00621;ART &#x00645;&#x00646; 10.4 &#x00639;&#x00627;&#x00645; (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627;&#x000a0;95%</styled-content>: 10.3&#x000a0;&#x00625;&#x00644;&#x00649;&#x000a0;10.5) &#x00625;&#x00644;&#x00649; 9.8&#x000a0;&#x00639;&#x00627;&#x00645; (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627;&#x000a0;95%</styled-content>: &#x000a0;9.6&#x000a0;&#x00625;&#x00644;&#x00649;&#x000a0;10.0). &#x00648;&#x00632;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062e;&#x00631; &#x00641;&#x0064a; &#x00628;&#x0062f;&#x00621; ART &#x00645;&#x00646; 3.4&#x000a0;&#x00639;&#x00627;&#x00645; (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627;&#x000a0;95%</styled-content>: 3.1&#x000a0;&#x00625;&#x00644;&#x00649;&#x000a0;3.7) &#x00625;&#x00644;&#x00649; 5.8&#x000a0;&#x00639;&#x00627;&#x00645; (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627;&#x000a0;95%</styled-content>: 5.6&#x000a0;&#x00625;&#x00644;&#x00649;&#x000a0;6.2). </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x0062a;&#x00634;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00627;&#x00644;&#x00632;&#x00645;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00642;&#x0062f;&#x00631;&#x00629; &#x00644;&#x00628;&#x0062f;&#x00621;&#x000a0;ART &#x00648;&#x00644;&#x00644;&#x0062a;&#x00623;&#x0062e;&#x00631; &#x00641;&#x0064a; &#x00628;&#x0062f;&#x00621;&#x000a0;ART &#x00625;&#x00644;&#x00649; &#x00623;&#x00646; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x00645; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x0064a;&#x00631;&#x00648;&#x00646; &#x00644;&#x00627; &#x0064a;&#x00641;&#x0064a; &#x00628;&#x00627;&#x00644;&#x00627;&#x0062d;&#x0062a;&#x0064a;&#x00627;&#x0062c;&#x00627;&#x0062a;. &#x00648;&#x00645;&#x00646; &#x00627;&#x00644;&#x00645;&#x00641;&#x0062a;&#x00631;&#x00636; &#x00623;&#x00646; &#x0062a;&#x00633;&#x00627;&#x00639;&#x0062f; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00645;&#x00624;&#x00634;&#x00631;&#x00627;&#x0062a; &#x00639;&#x00644;&#x00649; &#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00625;&#x00630;&#x00627; &#x00645;&#x00627; &#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0062f;&#x0062e;&#x00644;&#x00627;&#x0062a; &#x00641;&#x0064a; &#x00645;&#x0062c;&#x00627;&#x00644; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00645;&#x00629; &#x00644;&#x00644;&#x00625;&#x00633;&#x00631;&#x00627;&#x00639; &#x00628;&#x00628;&#x0062f;&#x00621; ART &#x00646;&#x00627;&#x0062c;&#x0062d;&#x00629; &#x00628;&#x00627;&#x00644;&#x00641;&#x00639;&#x00644;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x04e3a;&#x076d1;&#x063a7;&#x04eba;&#x07c7b;&#x0514d;&#x075ab;&#x07f3a;&#x09677;&#x075c5;&#x06bd2; (HIV) &#x07684;&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x06cbb;&#x07597; (ART) &#x060c5;&#x051b5;&#x0800c;&#x063d0;&#x051fa;&#x04e24;&#x04e2a;&#x065b0;&#x06307;&#x06807;&#x0ff1b;(i)&#x000a0;&#x04ece; HIV &#x08840;&#x06e05;&#x08f6c;&#x05316;&#x05230; ART &#x05f00;&#x059cb;&#x07684;&#x065f6;&#x095f4;&#x0ff0c;&#x0548c; (ii)&#x000a0;&#x04ece; ART &#x05408;&#x0683c;&#x05230;&#x05f00;&#x059cb;&#x07684;&#x065f6;&#x095f4;&#x0ff0c;&#x04e5f;&#x079f0;&#x04e3a; ART &#x05f00;&#x059cb;&#x065f6;&#x095f4;&#x05ef6;&#x08fdf;&#x03002; &#x065e8;&#x05728;&#x08bc4;&#x04ef7;&#x05580;&#x09ea6;&#x09686;&#x05883;&#x05185;&#x08fd9;&#x04e9b;&#x06307;&#x06807;&#x0503c;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x07528;&#x07ebf;&#x06027;&#x056de;&#x05f52;&#x06cd5;&#x05efa;&#x07acb;&#x04e86; HIV &#x0611f;&#x067d3;&#x08005;&#x04f53;&#x05185;&#x07684; CD4+ T &#x06dcb;&#x05df4;&#x07ec6;&#x080de;&#x0ff08;CD4+ &#x07ec6;&#x080de;&#x0ff09;&#x06570;&#x05728;&#x04e00;&#x06bb5;&#x065f6;&#x095f4;&#x05185;&#x05448;&#x081ea;&#x07136;&#x09012;&#x051cf;&#x07684;&#x06a21;&#x0578b;&#x03002; &#x08be5;&#x06a21;&#x0578b;&#x062df;&#x05408;&#x04ece;&#x079d1;&#x07279;&#x08fea;&#x074e6;&#x05883;&#x05185;&#x000a0;351&#x000a0;&#x0540d;&#x04eba;&#x05458;&#x04e2d;&#x091c7;&#x096c6;&#x07684;&#x06570;&#x0636e;&#x03002; &#x06211;&#x04eec;&#x04ee5;&#x05728;&#x05580;&#x09ea6;&#x09686;&#x05883;&#x05185;&#x04e8e;&#x000a0;2007&#x000a0;&#x05e74;&#x081f3;&#x000a0;2010&#x000a0;&#x05e74;&#x0671f;&#x095f4;&#x063a5;&#x053d7; ART &#x07684;&#x000a0;4154&#x000a0;&#x0540d; HIV &#x060a3;&#x08005;&#x04e3a;&#x04ee3;&#x08868;&#x06027;&#x06837;&#x0672c;&#x0ff0c;&#x091c7;&#x07528;&#x08be5;&#x06a21;&#x0578b;&#x06765;&#x04f30;&#x08ba1;&#x08840;&#x06e05;&#x08f6c;&#x05316;&#x05230; ART &#x05f00;&#x059cb;&#x07684;&#x065f6;&#x095f4;&#x04ee5;&#x053ca; ART &#x05f00;&#x059cb;&#x065f6;&#x095f4;&#x07684;&#x05ef6;&#x08fdf;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05728;&#x05580;&#x09ea6;&#x09686;&#x05883;&#x05185;&#x0ff0c;ART &#x05f00;&#x059cb;&#x065f6;&#x07684; CD4+ &#x07ec6;&#x080de;&#x08ba1;&#x06570;&#x04e2d;&#x0503c;&#x04ece;&#x000a0;2007&#x000a0;&#x05e74;&#x081f3;&#x000a0;2009&#x000a0;&#x05e74;&#x07684;&#x000a0;cells/&#x003bc;l&#x0ff08;&#x056db;&#x05206;&#x04f4d;&#x05dee;&#x0ff1a;IQR&#x0ff1a; 66&#x000a0;&#x081f3;&#x000a0;210&#x0ff09;&#x0589e;&#x052a0;&#x081f3;&#x000a0;2010&#x000a0;&#x05e74;&#x07684;&#x000a0;163 cells/&#x003bc;l&#x0ff08;IQR&#x0ff1a; 73&#x000a0;&#x081f3;&#x000a0;260&#x0ff09;&#x03002;&#x04ece;&#x08840;&#x06e05;&#x08f6c;&#x05316;&#x05230; ART &#x05f00;&#x059cb;&#x07684;&#x04f30;&#x08ba1;&#x05e73;&#x05747;&#x065f6;&#x095f4;&#x04ece;&#x000a0;10.4&#x000a0;&#x05e74;&#x0ff08;95%&#x000a0;&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;&#x0ff0c;CI&#x0ff1a; 10.3 &#x081f3; 10.5&#x0ff09;&#x04e0b;&#x0964d;&#x081f3;&#x000a0;9.8&#x000a0;&#x05e74;&#x0ff08;95%&#x000a0;CI&#x0ff1a; 9.6&#x000a0;&#x081f3;&#x000a0;10.0&#x0ff09;&#x03002; ART &#x07684;&#x05f00;&#x059cb;&#x065f6;&#x095f4;&#x05ef6;&#x08fdf;&#x04ece;&#x000a0;3.4&#x000a0;&#x05e74;&#x0ff08;95%&#x000a0;CI&#x0ff1a; 3.1&#x000a0;&#x081f3;&#x000a0;3.7&#x0ff09;&#x0589e;&#x052a0;&#x081f3;&#x000a0;5.8&#x000a0;&#x05e74;&#x0ff08;95%&#x000a0;CI&#x0ff1a; 5.6&#x000a0;&#x081f3;&#x000a0;6.2&#x0ff09;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x05f00;&#x059cb; ART &#x07684;&#x09884;&#x08ba1;&#x065f6;&#x095f4;&#x0548c; ART &#x05f00;&#x059cb;&#x065f6;&#x095f4;&#x07684;&#x05ef6;&#x08fdf;&#x08868;&#x0660e;&#x05580;&#x09ea6;&#x09686;&#x05883;&#x05185;&#x05e76;&#x0672a;&#x053d6;&#x05f97;&#x08db3;&#x0591f;&#x07684;&#x08fdb;&#x06b65;&#x03002; &#x08fd9;&#x04e9b;&#x06307;&#x06807;&#x05e94;&#x06709;&#x052a9;&#x04e8e;&#x076d1;&#x063a7;&#x0516c;&#x05171;&#x0536b;&#x0751f;&#x05e72;&#x09884;&#x063aa;&#x065bd;&#x0662f;&#x05426;&#x080fd;&#x0591f;&#x06210;&#x0529f;&#x052a0;&#x05feb; ART &#x07684;&#x05f00;&#x059cb;&#x065f6;&#x095f4;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041f;&#x00440;&#x00435;&#x00434;&#x0043b;&#x0043e;&#x00436;&#x00438;&#x00442;&#x0044c; &#x00434;&#x00432;&#x00430; &#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00445; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044f; &#x00434;&#x0043b;&#x0044f; &#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00440;&#x0043e;&#x0043b;&#x0044f; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x0043e;&#x00439; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x00438; (&#x00410;&#x00420;&#x00412;&#x00422;), &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043d;&#x00430;&#x00437;&#x0043d;&#x00430;&#x00447;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00434;&#x0043b;&#x0044f; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x00430; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043e;&#x00434;&#x00435;&#x00444;&#x00438;&#x00446;&#x00438;&#x00442;&#x00430; &#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;&#x00430; (&#x00412;&#x00418;&#x00427;): (i)&#x000a0;&#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x0043e;&#x00442; &#x00441;&#x00435;&#x00440;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00432;&#x00435;&#x00440;&#x00441;&#x00438;&#x00438;&#x000a0;&#x00412;&#x00418;&#x00427; &#x00434;&#x0043e; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00438; (ii)&#x000a0;&#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x00441; &#x0043c;&#x0043e;&#x0043c;&#x00435;&#x0043d;&#x00442;&#x00430; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00438;&#x0044f; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x00430; &#x0043a;&#x00440;&#x00438;&#x00442;&#x00435;&#x00440;&#x00438;&#x0044f;&#x0043c; &#x0043d;&#x00430;&#x00437;&#x0043d;&#x00430;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00434;&#x0043e; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x00438;, &#x0043d;&#x00430;&#x00437;&#x0044b;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00435; &#x00437;&#x00430;&#x00434;&#x00435;&#x00440;&#x00436;&#x0043a;&#x0043e;&#x00439; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422;. &#x0041e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x00442;&#x0044c; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439; &#x00432; &#x0041a;&#x00430;&#x0043c;&#x00435;&#x00440;&#x00443;&#x0043d;&#x00435;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00411;&#x0044b;&#x0043b;&#x0043e; &#x00441;&#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043e; &#x00435;&#x00441;&#x00442;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00435; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00441; &#x00442;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00432;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x00438; &#x00447;&#x00438;&#x00441;&#x0043b;&#x00430; T-&#x0043b;&#x00438;&#x0043c;&#x00444;&#x0043e;&#x00446;&#x00438;&#x00442;&#x0043e;&#x00432;&#x000a0;CD4+ (&#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;&#x000a0;CD4+) &#x00443; &#x00438;&#x0043d;&#x00444;&#x00438;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00412;&#x00418;&#x00427; &#x0043f;&#x00440;&#x00438; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x00438; &#x0043b;&#x00438;&#x0043d;&#x00435;&#x00439;&#x0043d;&#x0043e;&#x00439; &#x00440;&#x00435;&#x00433;&#x00440;&#x00435;&#x00441;&#x00441;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438;. &#x0041c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x0044c; &#x0043a;&#x0043e;&#x00440;&#x00440;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00441; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442;&#x0044b; &#x00438;&#x00437; 351&#x000a0;&#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;&#x00430; &#x00432; &#x0041a;&#x0043e;&#x00442;-&#x00434;&#x02019;&#x00418;&#x00432;&#x00443;&#x00430;&#x00440;&#x00435;. &#x0041c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x0044c; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x0044f;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00434;&#x0043b;&#x0044f; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438; &#x00432;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00442;&#x00440;&#x00435;&#x00437;&#x0043a;&#x00430; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; &#x00441;&#x00435;&#x00440;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00432;&#x00435;&#x00440;&#x00441;&#x00438;&#x00435;&#x00439; &#x00438; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x0043e;&#x0043c;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00437;&#x00430;&#x00434;&#x00435;&#x00440;&#x00436;&#x0043a;&#x00438; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00432; &#x00440;&#x00435;&#x0043f;&#x00440;&#x00435;&#x00437;&#x00435;&#x0043d;&#x00442;&#x00430;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x0044b;&#x00431;&#x0043e;&#x00440;&#x0043a;&#x00435; &#x00438;&#x00437; 4154&#x000a0;&#x00412;&#x00418;&#x00427;-&#x00438;&#x0043d;&#x00444;&#x00438;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445;, &#x0043d;&#x00430;&#x00447;&#x00430;&#x00432;&#x00448;&#x00438;&#x00445;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00432; &#x0041a;&#x00430;&#x0043c;&#x00435;&#x00440;&#x00443;&#x0043d;&#x00435; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; 2007&#x000a0;&#x00438; 2010&#x000a0;&#x00433;&#x00433;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00412; &#x0041a;&#x00430;&#x0043c;&#x00435;&#x00440;&#x00443;&#x0043d;&#x00435; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00435; &#x00447;&#x00438;&#x00441;&#x0043b;&#x0043e; &#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;&#x000a0;CD4+ &#x00432; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00435;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00443;&#x00432;&#x00435;&#x0043b;&#x00438;&#x00447;&#x00438;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x00441; 140&#x000a0;&#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;/&#x003bc;&#x0043b; (&#x0043c;&#x00435;&#x00436;&#x0043a;&#x00432;&#x00430;&#x00440;&#x00442;&#x00438;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x00440;&#x00430;&#x00437;&#x0043c;&#x00430;&#x00445;, &#x0041c;&#x0041a;&#x00420;: 66&#x02013;210) &#x00432; 2007&#x02013;2009&#x000a0;&#x00433;&#x00433;. &#x00434;&#x0043e; 163&#x000a0;&#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;/&#x003bc;&#x0043b; (&#x0041c;&#x0041a;&#x00420;: 73&#x02013;260) &#x00432; 2010&#x000a0;&#x00433;. &#x00412;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00435; &#x00441;&#x00440;&#x00435;&#x00434;&#x0043d;&#x00435;&#x00435; &#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x0043e;&#x00442; &#x00441;&#x00435;&#x00440;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00432;&#x00435;&#x00440;&#x00441;&#x00438;&#x00438; &#x00434;&#x0043e; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00441;&#x0043e;&#x0043a;&#x00440;&#x00430;&#x00442;&#x00438;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x00441; 10,4&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430; (95% &#x00434;&#x0043e;&#x00432;&#x00435;&#x00440;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x00438;&#x0043d;&#x00442;&#x00435;&#x00440;&#x00432;&#x00430;&#x0043b;, &#x00414;&#x00418;: 10,3&#x02013;10,5) &#x00434;&#x0043e; 9,8&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430; (95% &#x00414;&#x00418;: 9,6&#x02013;10,0). &#x00417;&#x00430;&#x00434;&#x00435;&#x00440;&#x00436;&#x0043a;&#x00430; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00443;&#x00432;&#x00435;&#x0043b;&#x00438;&#x00447;&#x00438;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00441; 3,4&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430; (95% &#x00414;&#x00418;: 3,1&#x02013;3,7) &#x00434;&#x0043e; 5,8&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430; (95% &#x00414;&#x00418;: 5,6&#x02013;6,2).</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x0041f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x00438; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00438; &#x00437;&#x00430;&#x00434;&#x00435;&#x00440;&#x00436;&#x0043a;&#x00438; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00443;&#x0043a;&#x00430;&#x00437;&#x0044b;&#x00432;&#x00430;&#x0044e;&#x00442; &#x0043d;&#x00430; &#x0043d;&#x00435;&#x00434;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00447;&#x0043d;&#x0044b;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00435;&#x00441;&#x00441; &#x00432; &#x0041a;&#x00430;&#x0043c;&#x00435;&#x00440;&#x00443;&#x0043d;&#x00435;. &#x0042d;&#x00442;&#x00438; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00438; &#x00434;&#x0043e;&#x0043b;&#x00436;&#x0043d;&#x0044b; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00447;&#x0044c; &#x00432; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00435; &#x00443;&#x00441;&#x0043f;&#x00435;&#x00448;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043c;&#x00435;&#x00440;&#x0043e;&#x0043f;&#x00440;&#x00438;&#x0044f;&#x00442;&#x00438;&#x00439; &#x00432; &#x0043e;&#x00431;&#x0043b;&#x00430;&#x00441;&#x00442;&#x00438; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x0043d;&#x00430;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043d;&#x00430; &#x00443;&#x00441;&#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Early initiation of antiretroviral treatment (ART) is needed to reduce morbidity and mortality from human immunodeficiency virus (HIV) infection and to reduce HIV transmission.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R2" ref-type="bibr"><sup>2</sup></xref> The CD4+ T-lymphocyte (CD4+ cell) threshold for ART eligibility in World Health Organization (WHO) guidelines have changed several times. In 2006, HIV-infected individuals with 200&#x000a0;CD4+ cells/&#x003bc;L or less were eligible for ART. In 2010, 350&#x000a0;cells/&#x003bc;L was the threshold. In 2013, the threshold was raised to 500&#x000a0;cells/&#x003bc;L, but the guidance was to prioritize individuals with advanced HIV disease or less than 350 cells/&#x003bc;L.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref><sup>&#x02013;</sup><xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>These changes in ART eligibility coincided with rapid scaling-up of ART in low- and middle-income countries. In sub-Saharan Africa, the number of people receiving ART increased from 100&#x02009;000 in 2003 to 9.0 million in 2013.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> Between 2006 and 2011, the median CD4+ cell count increased from 238 to 286 cells/&#x003bc;L at enrolment into care and from 125 to 185 cells/&#x003bc;L at ART initiation.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="R8" ref-type="bibr"><sup>8</sup></xref> Thus, many people living with HIV started ART below the WHO-recommended CD4+ cell count threshold, which indicates a gap between ART guidelines and reality.</p><p>Measuring this gap at the population level and its changes over time is important to effectively monitor and evaluate programmes aimed at reducing late ART initiation. Generally, the timeliness of ART initiation is assessed by analysing the distribution of CD4+ cell counts at ART initiation and access to ART is measured by ART coverage, defined as the number of individuals receiving ART among those eligible.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> However, these indicators do not quantify the time between becoming HIV-infected and the actual ART initiation nor do they measure how much time is lost between the moment &#x02013; usually unobserved &#x02013; when HIV-infected people reach the ART eligibility threshold and when they actually start receiving ART. Here, we propose two new population-level indicators to measure these times among HIV-infected people initiating ART: (i)&#x000a0;the time from HIV seroconversion &#x02013; i.e. the time at which the body produces detectable antibodies to HIV &#x02013; to ART initiation; and (ii)&#x000a0;the delay in ART initiation, i.e. the time between eligibility for ART and initiation of ART. To give an example, we estimated these indicators for Cameroon, where ART became freely available in May 2007 and the number of people living with HIV and receiving ART increased from 17&#x02009;000 in 2005 to 132&#x02009;000 by the end of 2013.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref></p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Data sources</title><p>Our approach requires two data sets. First, data on CD4+ cell counts at ART initiation among individuals who are representative of the population of interest. Second, data on the natural history of the CD4+ cell count decline during HIV infection.</p><p>The first data set was obtained from a survey conducted in a representative sample of 55 HIV-care facilities in Cameroon. The design of this survey has been described elsewhere.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Briefly, the medical records of 4154 people older than 15&#x000a0;years, living with HIV and who started ART in the month of October in the years 2007&#x02013;2010 were reviewed to obtain sociodemographic and CD4+ cell count data, including gender, age at ART initiation, date of ART initiation and CD4+ cell count before ART initiation. Most participants were women (2829, 68.1%), and median age at ART initiation was 35&#x000a0;years (<xref ref-type="table" rid="T1">Table&#x000a0;1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table&#x000a0;1</label><caption><title>Characteristics of people living with HIV who started antiretroviral treatment, and had a measure of CD4+ cell count at treatment initiation, Cameroon 2007&#x02013;2010</title></caption><table frame="hsides" rules="groups"><col width="291" span="1"/><col width="110" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">People who started ART <italic>n</italic>&#x02009;=&#x02009;4154</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Number of women (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">2829 (68.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Median age at ART initiation, years (IQR)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">35.0 (29.0 to 43.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Median CD4+ cell count at ART initiation, cells/</bold><bold>&#x003bc;L</bold><bold> (IQR)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">2007&#x02013;2009</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;All</td><td valign="top" align="center" rowspan="1" colspan="1">140 (66 to 210)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Women</td><td valign="top" align="center" rowspan="1" colspan="1">147 (73 to 215)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Men</td><td valign="top" align="center" rowspan="1" colspan="1">123 (53 to 198)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;All</td><td valign="top" align="center" rowspan="1" colspan="1">163 (73 to 260)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Women</td><td valign="top" align="center" rowspan="1" colspan="1">170 (78 to 263)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">147 (69 to 239)</td></tr></tbody></table><table-wrap-foot><p>ART: antiretroviral therapy; HIV: human immunodeficiency virus; IQR: interquartile range. </p><p>Notes: People included in the study were older than 15 years and started ART in the month of October each year. The ART eligibility threshold was 200 cells/&#x003bc;L in 2007&#x02013;2009 and 350 cells/&#x003bc;L in 2010.</p></table-wrap-foot></table-wrap><p>The second data set can be obtained from an observational cohort including individuals with a known or reliably estimated date of HIV seroconversion and repeated measurements of the CD4 cell count over time. As there was no such cohort study in Cameroon, we used data from a cohort of blood donors who had documented seroconversion between donations in C&#x000f4;te d&#x02019;Ivoire (ANRS 1220 Primo-CI study).<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> Blood donors had been invited to participate if they met the following criteria: diagnosed with HIV during a blood donation; HIV-seronegative at the preceding donation; less than 36 months had elapsed since seroconversion. The date of seroconversion was estimated as the midpoint between the last negative and the first positive HIV test. We used data on 351 cohort participants in our analyses, with 3037 CD4+ cell count measurements before ART initiation or death; CD4+ cell counts obtained more than 10&#x000a0;years after seroconversion were discarded to avoid a selection bias for slow progressors. Median age at seroconversion was 28.8&#x000a0;years and 60.7% (213) were men (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>). </p><table-wrap id="T2" orientation="portrait" position="float"><label>Table&#x000a0;2</label><caption><title>Characteristics of ANRS 1220 Primo-CI cohort participants in C&#x000f4;te d&#x02019;Ivoire</title></caption><table frame="hsides" rules="groups"><col width="359" span="1"/><col width="127" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Cohort participants <italic>n</italic>&#x02009;=&#x02009;351</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Number of women (%)</td><td valign="top" align="center" rowspan="1" colspan="1">138 (39.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median age at seroconversion, years (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">28.8 (24.5 to 34.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median time between last negative and first positive HIV test, months (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">8.5 (3.4 to 20.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median time between estimated date of seroconversion and cohort inclusion, months (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">9.0 (4.9 to 18.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median CD4+ cell count at cohort inclusion, cell/&#x003bc;L (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">450 (313 to 612)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median number of CD4+ cell count measurements (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">8.0 (3.0 to 13.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median time between two consecutive CD4+ cell count measurements, months (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">6.0 (5.9 to 6.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median cohort follow-up, years (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">5.6 (3.6 to 8.2)</td></tr></tbody></table><table-wrap-foot><p>HIV: human immunodeficiency virus; IQR: interquartile range.</p><p>Data sources: ANRS 1220 Primo-CI.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref></p></table-wrap-foot></table-wrap><p>The median time between the last negative and first positive HIV test was 8.5&#x000a0;months and the median time from seroconversion to inclusion into the cohort was 9.0&#x000a0;months. The median CD4+ cell count at cohort inclusion was 450&#x000a0;cells/&#x003bc;L and the median number of CD4+ cell measurements per individual was eight.</p><p>Blood samples from the participants were collected at inclusion into the cohort and every six&#x000a0;months thereafter to measure the CD4+ cell count.</p></sec><sec><title>Analyses</title><p>The analysis was completed in three steps. First, we modelled the natural decline in CD4+ cell counts in HIV-infected individuals who had not yet received ART, using data from the seroconversion cohort. Second, we used the model to estimate the average time from seroconversion to eligibility for ART in this cohort. Third, we used the model and data on CD4+ cell counts at ART initiation in Cameroon to estimate the average time between seroconversion and ART initiation in Cameroon. Then, we calculated the delay in ART initiation in Cameroon by subtracting the average time between HIV seroconversion and ART eligibility from the average time between HIV seroconversion and ART initiation.</p><p>We first used a linear mixed model<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> to describe the natural decline in CD4+ cell numbers in ART-na&#x000ef;ve HIV-infected individuals with estimated dates of HIV seroconversion and repeated measurements of the CD4+ cell count over time. To take into account the correlation of repeated measurements in a given individual, the parameters were allowed to vary from one individual to another through a random intercept and slope. CD4+ cell count data were square-root transformed to normalize their distribution.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> The model equations are as follows:<disp-formula id="E1"><graphic xlink:href="BLT.14.147892-M1.jpg" position="anchor" orientation="portrait"/><label>(1)</label></disp-formula>where <italic>CD</italic>4<italic><sub>ij</sub></italic> is the CD4+ cell count measured at the <italic>j</italic>th visit of the <italic>i</italic>th individual, <italic>CD</italic>4<italic><sub>i</sub></italic><sub>0</sub> is the estimated CD4+ cell count at HIV seroconversion, defined as time 0 in the model; <italic>&#x003b2;<sub>i</sub></italic><sub>1</sub> is the CD4+ cell count slope; <italic>t<sub>ij</sub></italic> is the interval from the estimated date of seroconversion to the <italic>j</italic>th visit; and <italic>&#x003b5;<sub>ij</sub></italic> is the residual error.</p><p>Both the CD4+ cell count at seroconversion and the CD4+ slope may be influenced by covariates. <italic>x<sub>ijk</sub></italic> represents the <italic>k</italic>th covariate; <italic>&#x003b1;<sub>k</sub></italic> and <italic>&#x003b2;<sub>k</sub></italic> are respectively the fixed-effect intercept and slope for the <italic>k</italic>th covariate; <italic>&#x003b1;<sub>0</sub></italic> and <italic>&#x003b2;<sub>0</sub></italic> are respectively the baseline intercept and slope; and <italic>b<sub>i0</sub></italic> and <italic>b<sub>i</sub></italic><sub>1</sub> are respectively the random intercept and slope for the <italic>i</italic>th individual.</p><p><italic>&#x003b5;<sub>ij</sub></italic>, <italic>b<sub>i</sub></italic><sub>0</sub> and <italic>b<sub>i</sub></italic><sub>1</sub> were assumed to be normally distributed. The correlation between individual CD4+ cell counts at seroconversion and subsequent individual slopes was handled through an unstructured covariance matrix of random effects.</p><p>From <xref ref-type="disp-formula" rid="E1">Equation&#x000a0;(1)</xref>, we derived the time from seroconversion to any given CD4+ cell count:<disp-formula id="E2"><graphic xlink:href="BLT.14.147892-M2.jpg" position="anchor" orientation="portrait"/><label>(2)</label></disp-formula>where <italic>CD</italic>4<italic><sub>x</sub></italic> is a given CD4+ cell count, <italic>E</italic>(&#x0221a;CD4<italic><sub>i</sub></italic><sub>0</sub>) and <italic>E</italic>(<italic>&#x003b2;<sub>i</sub></italic><sub>1</sub>) are expected values of &#x0221a;CD4<italic><sub>i</sub></italic><sub>0</sub> (the square root of the CD4+ cell counts at seroconversion) and <italic>&#x003b2;<sub>i</sub></italic><sub>1</sub>, (rate of CD4+ cell count decline) obtained by fitting <xref ref-type="disp-formula" rid="E1">Equation&#x000a0;(1)</xref> to data from seroconverters.</p><p>Second, we used <xref ref-type="disp-formula" rid="E2">Equation&#x000a0;(2)</xref>, to calculate, for each seroconverter, the time from seroconversion to specified CD4+ count thresholds. From these individual times we calculated the average time from seroconversion to ART eligibility.</p><p>Third, we calculated the time from seroconversion to ART initiation, using <xref ref-type="disp-formula" rid="E2">Equation&#x000a0;(2)</xref>, we need to know the CD4+ cell count at ART initiation, the CD4+ cell count at HIV seroconversion and the average rate of CD4+ cell count decline. Many HIV-infected individuals starting ART have only one available CD4+ cell count before ART initiation, because they are already eligible for ART when HIV infection is diagnosed. Thus, the CD4+ cell count at seroconversion and the rate of CD4+ cell count decline are both unknown. We generated the values of these two parameters for each HIV-infected individual starting ART by using data from seroconverters.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> Specifically, for each individual included in the survey conducted in Cameroon, we simulated 200 sets of CD4+ cell count values at seroconversion and rates of CD4+ cell count decline, as follows. Square-root transformed values of the CD4+ cell count at HIV seroconversion and CD4+ cell count slopes in ANRS 1220 Primo-CI cohort participants were fitted with a joint bivariate normal distribution.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> This distribution was used to simulate the 200 sets of values for each surveyed individual. Using each set of values, along with CD4+ cell counts measured at ART initiation and <xref ref-type="disp-formula" rid="E2">Equation&#x000a0;(2)</xref>, we calculated, for each surveyed individual, 200 time intervals between seroconversion and ART initiation. We estimated the average time from seroconversion to ART initiation by averaging the results for each surveyed individual. Finally, we calculated the delay in ART initiation.</p><p>The eligibility for ART initiation in Cameroon was raised from 200 to 350&#x000a0;cells/&#x003bc;L in August 2010. We therefore calculated the average time from seroconversion to ART initiation and delay in ART initiation using the estimated average time from seroconversion to 200&#x000a0;cells/&#x003bc;L for individuals who initiated ART before August 2010. For individuals who initiated ART after August 2010, we used the estimated average time from seroconversion to 350&#x000a0;cells/&#x003bc;L.</p><p>To assess the robustness of our results, we performed sensitivity analyses which considered two scenarios of HIV virulence. First we assumed higher virulence leading to 5% lower CD4+ cell count at HIV seroconversion and 5% higher CD4+ cell count slope. Second we assumed lower virulence leading to 5% higher CD4+ count at HIV seroconversion and 5% lower CD4+ cell count slope. These assumptions were motivated by findings that showed a 25% decrease in the CD4+ count at seroconversion over more than 20&#x000a0;years,<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> while our study only considered individuals who initiated ART between 2007 and 2010. We compared the results from the sensitivity analyses with the main estimates using the <italic>Z</italic>-test. All analyses were performed using Stata version 11.1 (StataCorp. LP, College Station, United States of America).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Model fitting</title><p>By fitting the mixed model to the seroconverter data, we estimated that the mean CD4+ cell count at seroconversion was 539&#x000a0;cells/&#x003bc;L (95% confidence intervals, CI: 516 to 562) and that the mean CD4+ cell decline in the first year after seroconversion was 53&#x000a0;cells/&#x003bc;L (95% CI: 51 to 56). Higher CD4+ cell counts at cohort inclusion and longer intervals from seroconversion to cohort inclusion were associated with higher CD4+ cell counts at seroconversion (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; <xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). In addition, higher CD4+ cell counts at cohort inclusion were associated with a more rapid CD4+ cell decline (<italic>P</italic>&#x02009;=&#x02009;0.009; <xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). None of the other covariates was significantly associated with the intercept or slope.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table&#x000a0;3</label><caption><title>Influence of selected characteristics of ANRS 1220 Primo-CI cohort participants on the CD4+ cell count at seroconversion and its slope, as estimated from the linear mixed model</title></caption><table frame="hsides" rules="groups"><col width="284" span="1"/><col width="158" span="1"/><col width="65" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Effect</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Coefficient (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Fixed effect</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Square-root CD4+ cell count intercept</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">12.035 (11.358 to 12.712)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CD4+ cell count at cohort inclusion (per 1 cell/&#x003bc;L increase)</td><td valign="top" align="center" rowspan="1" colspan="1">0.020 (0.019 to 0.021)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Time from HIV seroconversion to cohort inclusion (per one-year increase)</td><td valign="top" align="center" rowspan="1" colspan="1">0.973 (0.672 to 1.273)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Square-root CD4+ cell count slope (cells/&#x003bc;L decrease per year)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.676 (&#x02212;0.972 to &#x02212;0.379)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CD4+ cell count at cohort inclusion (per 1 cell/&#x003bc;L increase)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.001 (&#x02212;0.001 to &#x02212;0.000)</td><td valign="top" align="center" rowspan="1" colspan="1">0.009<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Time from HIV seroconversion to cohort inclusion (per one-year increase)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.065 (&#x02212;0.186 to 0.056)</td><td valign="top" align="center" rowspan="1" colspan="1">0.292<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Random effect</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Intercept variance</td><td valign="top" align="center" rowspan="1" colspan="1">2.007 (1.390 to 2.898)</td><td rowspan="3" valign="top" align="left" colspan="1">&#x0003c;&#x02009;0.001<sup>b</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Slope variance</td><td valign="top" align="center" rowspan="1" colspan="1">0.525 (0.394 to 0.701)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Covariance between intercept and slope</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.165 (&#x02212;0.430 to 0.101)</td></tr></tbody></table><table-wrap-foot><p>CI: confidence interval; HIV: human immunodeficiency virus.</p><p><sup>a</sup> Wald test.</p><p><sup>b</sup> The likelihood ratio test rejected the null hypothesis that all coefficients were simultaneously equal to 0.</p><p>Note: The following variables: age at seroconversion, gender, CD4+ cell count at cohort inclusion and time from seroconversion to cohort inclusion, were initially included in the multivariable analysis. We used a backward stepwise selection procedure in the final model to retain only those covariates significantly associated (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) with the intercept and slope.</p></table-wrap-foot></table-wrap></sec><sec><title>Time to ART eligibility</title><p>We replaced the parameters in <xref ref-type="disp-formula" rid="E2">Equation&#x000a0;(2)</xref> with their estimates from the previous step to calculate the time from HIV seroconversion to ART eligibility:<disp-formula id="E3"><graphic xlink:href="BLT.14.147892-M3.jpg" position="anchor" orientation="portrait"/><label>(3)</label></disp-formula>where <italic>CD</italic>4<italic><sub>x</sub></italic> is the CD4+ cell count ART eligibility threshold, t<italic><sub>i</sub></italic><sub>1</sub> is the estimated number of years from seroconversion to cohort inclusion, and <italic>CD</italic>4<italic><sub>i</sub></italic><sub>1</sub> is the CD4+ cell count at cohort inclusion.</p><p>The average times from seroconversion to CD4+ cell counts of less than 350 and &#x02009;200&#x000a0;cells/&#x003bc;L were 4.0 and 7.0&#x000a0;years, respectively. The corresponding median times were 3.8 and 7.1&#x000a0;years (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table&#x000a0;4</label><caption><title>Estimated time from HIV seroconversion to ART eligibility</title></caption><table frame="hsides" rules="groups"><col width="90" span="1"/><col width="8" span="1"/><col width="92" span="1"/><col width="92" span="1"/><col width="11" span="1"/><col width="92" span="1"/><col width="92" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">HIV sero-converters</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">2010 WHO ART eligibility threshold<sup>a</sup><hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">2006 WHO ART eligibility threshold<sup>b</sup><hr/></th></tr><tr><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Mean years (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Median years (IQR)</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Mean years (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Median years (IQR)</th></tr></thead><tbody><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">4.0 (3.7 to 4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3.8 (2.0 to 5.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">7.0 (6.8 to 7.3)</td><td valign="top" align="center" rowspan="1" colspan="1">7.1 (5.2 to 8.8)</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">Women</td><td valign="top" align="center" rowspan="1" colspan="1">4.1 (3.6 to 4.5)</td><td valign="top" align="center" rowspan="1" colspan="1">3.9 (2.2 to 5.9)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">7.0 (6.6 to 7.4)</td><td valign="top" align="center" rowspan="1" colspan="1">7.2 (5.3 to 8.7)</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">4.0 (3.6 to 4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3.7 (1.9 to 5.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">7.0 (6.7 to 7.4)</td><td valign="top" align="center" rowspan="1" colspan="1">7.1 (5.2 to 8.9)</td></tr></tbody></table><table-wrap-foot><p>ART: antiretroviral therapy; CI: confidence interval; HIV: human immunodeficiency virus; IQR: interquartile range; WHO: World Health Organization.</p><p><sup>a</sup> The threshold is a CD4+ cell count less than 350 cells/&#x003bc;L.</p><p><sup>b</sup> The threshold is a CD4+ cell count less than 200 cells/&#x003bc;L.</p></table-wrap-foot></table-wrap></sec><sec><title>Cameroon indicators</title><p>Women had a higher CD4+ cell count at ART initiation than men (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). The median CD4+ cell count at ART initiation increased significantly from 123&#x000a0;cells/&#x003bc;L in 2007&#x02013;2009 to 147&#x000a0;cells/&#x003bc;L in 2010 among men, and from 147&#x000a0;cells/&#x003bc;L in 2007&#x02013;2009 to 170&#x000a0;cells/&#x003bc;L in 2010 among women.</p><sec><title>Time to ART initiation</title><p>The estimated average time from seroconversion to ART initiation fell from 10.4&#x000a0;years (95% CI: 10.3 to 10.5) in 2007&#x02013;2009 to 9.8&#x000a0;years (95% CI: 9.6 to 10.0) in 2010 (<xref ref-type="table" rid="T5">Table&#x000a0;5</xref>); the corresponding median times were 9.9 and 9.2&#x000a0;years. The time was significantly shorter for women than men in 2007&#x02013;2009 (10.2 versus 10.9&#x000a0;years, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01), while the difference was no longer significant in 2010 (9.7 versus 10.0&#x000a0;years, <italic>P</italic>&#x02009;=&#x02009;0.36).</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table&#x000a0;5</label><caption><title>Estimated time from HIV seroconversion to antiretroviral treatment initiation and delay in antiretroviral treatment initiation, Cameroon, 2007&#x02013;2010</title></caption><table frame="hsides" rules="groups"><col width="78" span="1"/><col width="127" span="1"/><col width="120" span="1"/><col width="92" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Year of ART initiation</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Time from HIV seroconversion to ART initiation<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Delay in ART initiation<sup>a</sup> (95% CI)</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Mean years (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Median years (IQR)</th></tr></thead><tbody><tr><td valign="top" align="justify" scope="col" rowspan="1" colspan="1"><bold>2007&#x02013;2009</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">10.4 (10.3 to 10.5)</td><td valign="top" align="center" rowspan="1" colspan="1">9.9 (7.6 to 13.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3.4 (3.1 to 3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Women</td><td valign="top" align="center" rowspan="1" colspan="1">10.2 (10.0 to 10.3)</td><td valign="top" align="center" rowspan="1" colspan="1">9.7 (7.5 to 12.7)</td><td valign="top" align="center" rowspan="1" colspan="1">3.2 (2.8 to 3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">10.9 (10.6 to 11.1)</td><td valign="top" align="center" rowspan="1" colspan="1">10.6 (7.9 to 13.8)</td><td valign="top" align="center" rowspan="1" colspan="1">3.9 (3.5 to 4.3)</td></tr><tr><td valign="top" align="justify" scope="col" rowspan="1" colspan="1"><bold>2010</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">9.8 (9.6 to 10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">9.2 (6.6 to 12.7)</td><td valign="top" align="center" rowspan="1" colspan="1">5.8 (5.6 to 6.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Women</td><td valign="top" align="center" rowspan="1" colspan="1">9.7 (9.4 to 10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">9.1 (6.6 to 12.6)</td><td valign="top" align="center" rowspan="1" colspan="1">5.6 (5.2 to 6.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">10.0 (9.6 to 10.5)</td><td valign="top" align="center" rowspan="1" colspan="1">9.4 (6.8 to 12.9)</td><td valign="top" align="center" rowspan="1" colspan="1">6.0 (5.4 to 6.6)</td></tr></tbody></table><table-wrap-foot><p>ART: antiretroviral therapy; CI: confidence interval; HIV: human immunodeficiency virus; IQR: interquartile range.</p><p><sup>a</sup> The delay in ART initiation was calculated by subtracting the average time from seroconversion to ART eligibility from the average time between HIV seroconversion and ART initiation.</p><p>Note: The ART eligibility threshold was 200 cells/&#x003bc;L in 2007&#x02013;2009 and 350 cells/&#x003bc;L in 2010.</p></table-wrap-foot></table-wrap></sec><sec><title>Delay in ART initiation</title><p>The estimated delay in ART initiation is shown in <xref ref-type="table" rid="T5">Table&#x000a0;5</xref>. Overall, the delay increased from 3.4&#x000a0;years (95% CI: 3.1 to 3.7) in 2007&#x02013;2009 to 5.8&#x000a0;years (95% CI: 5.6 to 6.2) in 2010. Women had shorter delays than men (3.2 versus 3.9&#x000a0;years in 2007&#x02013;2009, and 5.6 versus 6.0&#x000a0;years in 2010).</p></sec></sec><sec><title>Sensitivity analyses</title><p>The results from our sensitivity analysis are shown in <xref ref-type="table" rid="T6">Table&#x000a0;6</xref>. Assuming a 5% increase in HIV virulence led to a 1.1&#x02013;1.3&#x000a0;year shorter average time from seroconversion to ART initiation, corresponding to an 11&#x02013;12% decrease (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). While assuming a 5% decrease in HIV virulence led to a 1.3&#x02013;1.4&#x000a0;year longer average time, corresponding to an 11&#x02013;14% increase (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). In contrast, the delay in ART initiation was not significantly changed under the two sensitivity analysis scenarios except for the overall value in 2010 (<italic>P</italic>&#x02009;=&#x02009;0.002) and the value among women in 2010 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), where we found a 9&#x02013;10 % decrease when assuming a 5% increase in HIV virulence and a 12&#x02013;13% increase when assuming a 5% decrease in HIV virulence.</p><table-wrap id="T6" orientation="portrait" position="float"><label>Table&#x000a0;6</label><caption><title>Sensitivity analyses of estimated time from HIV seroconversion to antiretroviral treatment initiation and delay in antiretroviral treatment initiation, Cameroon, 2007&#x02013;2010</title></caption><table frame="hsides" rules="groups"><col width="135" span="1"/><col width="126" span="1"/><col width="106" span="1"/><col width="122" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Year of ART initiation</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Time from HIV seroconversion to ART initiation<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Delay in ART initiation (95% CI)</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Mean years (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Median years (IQR)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Scenario with increase in HIV virulence<sup>a</sup></bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" scope="col" rowspan="1" colspan="1">2007&#x02013;2009</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">9.2 (9.0 to 9.3)***</td><td valign="top" align="center" rowspan="1" colspan="1">8.6 (6.5 to 11.6)</td><td valign="top" align="center" rowspan="1" colspan="1">3.2 (3.0 to 3.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Women</td><td valign="top" align="center" rowspan="1" colspan="1">9.0 (8.8 to 9.1)***</td><td valign="top" align="center" rowspan="1" colspan="1">8.4 (6.5 to 11.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3.0 (2.8 to 3.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">9.6 (9.4 to 9.8)***</td><td valign="top" align="center" rowspan="1" colspan="1">9.2 (6.8 to 12.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3.6 (3.4 to 3.8)</td></tr><tr><td valign="top" align="justify" scope="col" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">8.6 (8.4 to 8.9)***</td><td valign="top" align="center" rowspan="1" colspan="1">7.9 (5.6 to 11.3)</td><td valign="top" align="center" rowspan="1" colspan="1">5.2 (4.9 to 5.5)*</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Women</td><td valign="top" align="center" rowspan="1" colspan="1">8.5 (8.2 to 8.7)***</td><td valign="top" align="center" rowspan="1" colspan="1">7.8 (5.5 to 11.2)</td><td valign="top" align="center" rowspan="1" colspan="1">5.1 (4.8 to 5.4)*</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">8.9 (8.5 to 9.3)***</td><td valign="top" align="center" rowspan="1" colspan="1">8.3 (5.8 to 11.6)</td><td valign="top" align="center" rowspan="1" colspan="1">5.5 (5.0 to 6.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Scenario with decrease in HIV virulence<sup>b</sup></bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" scope="col" rowspan="1" colspan="1">2007&#x02013;2009</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">11.8 (11.6 to 11.9)***</td><td valign="top" align="center" rowspan="1" colspan="1">11.2 (8.7 to 14.8)</td><td valign="top" align="center" rowspan="1" colspan="1">3.7 (3.5 to 3.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Women</td><td valign="top" align="center" rowspan="1" colspan="1">11.6 (11.4 to 11.7)***</td><td valign="top" align="center" rowspan="1" colspan="1">10.9 (8.6 to 14.4)</td><td valign="top" align="center" rowspan="1" colspan="1">3.5 (3.3 to 3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">12.3 (12.0 to 12.6)***</td><td valign="top" align="center" rowspan="1" colspan="1">11.9 (9.0 to 15.6)</td><td valign="top" align="center" rowspan="1" colspan="1">4.2 (3.9 to 4.5)</td></tr><tr><td valign="top" align="justify" scope="col" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">11.1 (10.9 to 11.4)***</td><td valign="top" align="center" rowspan="1" colspan="1">10.4 (7.5 to 14.4)</td><td valign="top" align="center" rowspan="1" colspan="1">6.5 (6.2 to 6.8)**</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Women</td><td valign="top" align="center" rowspan="1" colspan="1">11.0 (10.7 to 11.3)***</td><td valign="top" align="center" rowspan="1" colspan="1">10.2 (7.4 to 14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">6.3 (5.9 to 6.7)*</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">11.4 (10.9 to 11.9)***</td><td valign="top" align="center" rowspan="1" colspan="1">10.8 (7.8 to 14.7)</td><td valign="top" align="center" rowspan="1" colspan="1">6.8 (6.2 to 7.4)</td></tr></tbody></table><table-wrap-foot><p>ART: antiretroviral treatment; CI: confidence interval; HIV: human immunodeficiency virus; IQR: interquartile range; *<italic>P</italic> &#x0003c;&#x02009;0.05; **<italic>P</italic> &#x0003c;&#x02009;0.02; ***<italic>P</italic> &#x0003c;&#x02009;0.0001.</p><p><sup>a</sup> We assumed 5% lower CD4+ count at HIV seroconversion and 5% higher CD4+ cell count slope.</p><p><sup>b</sup> We assumed 5% higher CD4+ count at HIV seroconversion and 5% lower CD4+ cell count slope.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Delays in starting ART are lost opportunities for both the individual and the community. Therefore expanding ART programmes and accelerating ART initiation will be important to control the HIV epidemic. Here, we propose a method to estimate two new population-level indicators. Delay in ART initiation quantifies the loss of opportunity for people living with HIV. The time from HIV seroconversion to ART initiation quantifies the number of years that HIV-infected individuals were able to transmit HIV.</p><p>Our approach requires two data sets. First, data on the natural history of the CD4+ cell count decline during HIV infection. Second, data on CD4+ cell counts at ART initiation among individuals who are representative of the population of interest. The first data set can be obtained from the cohort of seroconverters in a nearby country if not available in the country of interest. Such cohorts exist in low-, middle- and high-income countries.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="R18" ref-type="bibr"><sup>18</sup></xref> The second data set is collected in most countries, as CD4+ cell count is an important parameter for the decisions of ART initiation and clinical management,<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> even in countries implementing ART initiation regardless of CD4+ count levels. Thus, our approach can be used to estimate the delay in ART initiation in most settings.</p><p>Our approach is based on two main assumptions. First, we converted CD4+ cell counts into time since HIV seroconversion. We assumed that individuals with low CD4+ cell counts had been infected with HIV longer than individuals with high CD4+ cell counts. This is a reasonable assumption at the population level. Other studies have used a similar approach to estimate the time from seroconversion to ART eligibility at the population level.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Second, we assumed that all HIV-infected individuals are eligible for ART only when the CD4+ threshold is reached. In reality, some individuals with symptomatic HIV disease are eligible for ART regardless of CD4+ cell count.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref><sup>&#x02013;</sup><xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Therefore, we may have overestimated the average time from seroconversion to ART eligibility and thus underestimated the delay in ART initiation. We did not account for people that have not yet initiated ART or those who die before ART initiation. Furthermore, our approach does not account for what happens after ART initiation, such as treatment adherence.</p><p>In Cameroon, we found that the time between HIV seroconversion and ART initiation fell between 2007&#x02013;2009 and 2010. However, the delay in ART initiation increased during the same period because the ART eligibility threshold was lowered. We also found that women who started ART in 2007&#x02013;2009 had shorter delays than men, whereas no significant sex difference was found in 2010. This reflects a small sex difference in the CD4+ cell counts at ART initiation in 2010.</p><sec><title>Limitations</title><p>As there was no available cohort of seroconverters in Cameroon, we used data from a cohort in C&#x000f4;te d&#x02019;Ivoire. HIV type 1 (HIV-1) genetic diversity is high in Cameroon, while in C&#x000f4;te d&#x02019;Ivoire, the HIV-1 CRF 02_AG variant predominates.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R21" ref-type="bibr"><sup>21</sup></xref> However, a study conducted in Cameroon and Senegal showed no difference in clinical progression between patients infected with CRF 02_AG and patients infected with other variants.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> In addition, our estimates of the CD4+ cell count at seroconversion and the CD4+ cell count decline are similar to those obtained in other sub-Saharan countries,<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> suggesting that any differences in disease progression at the population level would be small. Finally, it is conceivable that HIV has become more or less virulent over the course of the pandemic.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref> Our sensitivity analyses showed that changes in HIV virulence affected the average time between HIV seroconversion and ART initiation, while the delay in ART initiation was less sensitive to assumptions about such changes.</p><p>The results from Cameroon show that some progress has been made in reducing late ART initiation. Changes in ART guidelines and decentralization of HIV care could have affected this decrease. In particular, as new guidelines were introduced, patients in care with CD4+ cell counts above 200&#x000a0;cells/&#x003bc;L could have become eligible for ART and thus received ART earlier. Likewise, decentralization of HIV care could have made ART available earlier at the rural level.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> However, the estimated time of approximately 10&#x000a0;years to initiate ART and approximately 6&#x000a0;years for the delay in ART initiation indicate that the progress is insufficient and calls for interventions that accelerate ART initiation in Cameroon.</p><p>In conclusion, to optimize the control of HIV infection both at individual and community level, ART initiation will need to accelerate to close the gap between the WHO-recommended and actual timing of ART initiation. The proposed indicators should help monitor whether public health interventions are successful in achieving these goals.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>We thank the Agence nationale de recherche sur le sida et les h&#x000e9;patites virales (ANRS) 1220 Primo-CI Group, the trained interviewers and supervisors and the medical staff from the following HIV treatment facilities: Medical Unit (MU) Baptist Nkwen, MU Cameroon Baptist Church Mboppi Douala, MU St Luc Mbalmayo, MU Police Yaound&#x000e9;, MU District Hospital Mbengwi, MU St Vincent Dschang, MU Baptist Muntengene, District Hospital (DH) Ambam, Accredited Treatment Centre (ATC) Bertoua, MU DH Poli, MU DH Ayos, MU DH Nylon, ATC General Hospital Yaound&#x000e9;, MU Presbyterian Church Sakbayeme, MU DH Messamena, MU DH Batouri, ATC Gynaecology-Obstetrics-Pediatrics Hospital Yaound&#x000e9;, MU St Albert-Le-Grand Douala, MU Mary Health Fontem, MU DH Foumban, MU DH Yabassi, ATC Ngaound&#x000e9;r&#x000e9;, ATC Ebolowa, MU DH Tombel, ATC Foundation Chantal Biya Yaound&#x000e9;, MU Foundation Chantal Biya Meyomessala, MU Catholic Tokomb&#x000e9;r&#x000e9;, MU DH Guider, MU DH Cit&#x000e9; Palmiers Douala, MU DH Bangoua, MU Baptist Banso-Kumbo, ATC Bamenda, MU DH Kumba, MU DH Nkambe, MU DH Mfou, ATC Laquintinie Douala, MU DH New-Bell Douala, MU Presbyterian Church Djoungolo Yaound&#x000e9;, ATC Central Hospital Yaound&#x000e9;, ATC Maroua, MU Ad Lucem Mbouda, MU DH Biyem-Assi Yaound&#x000e9;, MU DH Ndikinimeki, ATC Limbe, ATC Garoua, ATC Bafoussam, ATC Jamot Yaound&#x000e9;, MU DH Meiganga, MU DH Meyomessala, MU DH Kolofata, MU DH Bafut, MU DH Ebebda, MU Ad Lucem Efok, MU DH Bogo and MU Centre M&#x000e9;dico-Social University Ngaound&#x000e9;r&#x000e9;.</p><p>Authors are also affiliated as follows: XA, Programme ARNS Coop&#x000e9;ration C&#x000f4;te d&#x02019;Ivoire (PACCI), Abidjan, C&#x000f4;te d&#x02019;Ivoire; ED, Department of Infectious and Tropical Diseases, University Hospital, F-34000, Montpellier, France; SKS, Infectious Disease Unit, Yaound&#x000e9; Central Hospital, Yaound&#x000e9;, Cameroon; DG, Programme PACCI, Abidjan, C&#x000f4;te d&#x02019;Ivoire; AM Centre M&#x000e9;dical de Suivi de Donneurs de Sang (CMSDS), Abidjan, C&#x000f4;te d'Ivoire.</p></ack><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>This work was supported by Sidaction (AI-20-3/01649 and postdoctoral fellowship to VS), ANRS (postdoctoral fellowship to VS) and the French Ministry of Education, Research and Technology (PhD fellowship to JDAN).</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Cohen</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>YQ</given-names></string-name>, <string-name><surname>McCauley</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gamble</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hosseinipour</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Kumarasamy</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>; <collab>HPTN 052 Study Team</collab>. <article-title>Prevention of HIV-1 infection with early antiretroviral therapy.</article-title>
<source>N Engl J Med</source>. <year>2011</year>
<month>8</month>
<day>11</day>;<volume>365</volume>(<issue>6</issue>):<fpage>493</fpage>&#x02013;<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1105243</pub-id><pub-id pub-id-type="pmid">21767103</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Severe</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Juste</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Ambroise</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Eliacin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Marchand</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Apollon</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.</article-title>
<source>N Engl J Med</source>. <year>2010</year>
<month>7</month>
<day>15</day>;<volume>363</volume>(<issue>3</issue>):<fpage>257</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0910370</pub-id><pub-id pub-id-type="pmid">20647201</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="web">Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. Geneva: World Health Organization; 2006. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf">http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf</ext-link> [cited 2015 March 22].</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="web">Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. Geneva: World Health Organization; 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/arv/adult2010/en/">http://www.who.int/hiv/pub/arv/adult2010/en/</ext-link> [cited 2015 March 22].</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="web">Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf">http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf</ext-link> [cited 2015 March 22].</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="web">The GAP report. Geneva: UNAIDS; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/">http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/</ext-link> [cited 2015 March 22].</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Lahuerta</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ue</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Hoffman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Elul</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kulkarni</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal>
<article-title>The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?</article-title>
<source>J Health Care Poor Underserved</source>. <year>2013</year>
<month>2</month>;<volume>24</volume>(<issue>1</issue>):<fpage>359</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1353/hpu.2013.0014</pub-id><pub-id pub-id-type="pmid">23377739</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Lahuerta</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hoffman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Elul</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kulkarni</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Remien</surname>
<given-names>RH</given-names></string-name>, <etal>et al.</etal>; <collab>Multi-level determinants of late ART initiation in sub-Saharan Africa Team and</collab>; <collab>Identifying Optimal Models of HIV Care in sub-Saharan Africa Collaboration</collab>. <article-title>Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006&#x02013;2011: findings from four sub-saharan African countries.</article-title>
<source>Clin Infect Dis</source>. <year>2014</year>
<month>2</month>;<volume>58</volume>(<issue>3</issue>):<fpage>432</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit724</pub-id><pub-id pub-id-type="pmid">24198226</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Johnson</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Boulle</surname>
<given-names>A</given-names></string-name>. <article-title>How should access to antiretroviral treatment be measured?</article-title>
<source>Bull World Health Organ</source>. <year>2011</year>
<month>2</month>
<day>1</day>;<volume>89</volume>(<issue>2</issue>):<fpage>157</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.10.080911</pub-id><pub-id pub-id-type="pmid">21346928</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Ndawinz</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Chaix</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Koulla-Shiro</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Delaporte</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Okouda</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Abanda</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis.</article-title>
<source>J Antimicrob Chemother</source>. <year>2013</year>
<month>6</month>;<volume>68</volume>(<issue>6</issue>):<fpage>1388</fpage>&#x02013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkt011</pub-id><pub-id pub-id-type="pmid">23391713</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Minga</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Danel</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Abo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Dohoun</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Bonard</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Coulibaly</surname>
<given-names>A</given-names></string-name>, <etal>et al. </etal><collab>ANRS 1220 Study Group</collab>. <article-title>Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, C&#x000f4;te d&#x02019;Ivoire.</article-title>
<source>Bull World Health Organ</source>. <year>2007</year>
<month>2</month>;<volume>85</volume>(<issue>2</issue>):<fpage>116</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.06.032292</pub-id><pub-id pub-id-type="pmid">17308732</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Minga</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Lewden</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gabillard</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bomisso</surname>
<given-names>GI</given-names></string-name>, <string-name><surname>Toni</surname>
<given-names>TD</given-names></string-name>, <string-name><surname>Emi&#x000e8;me</surname>
<given-names>AA</given-names></string-name>, <etal>et al.</etal>; <collab>Agence Nationale de Recherches sur le Sida (ANRS) 1220 Primo-CI Study Group</collab>. <article-title>CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.</article-title>
<source>AIDS</source>. <year>2011</year>
<month>3</month>
<day>27</day>;<volume>25</volume>(<issue>6</issue>):<fpage>819</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32834625d3</pub-id><pub-id pub-id-type="pmid">21412060</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Laird</surname>
<given-names>NM</given-names></string-name>, <string-name><surname>Ware</surname>
<given-names>JH</given-names></string-name>. <article-title>Random-effects models for longitudinal data.</article-title>
<source>Biometrics</source>. <year>1982</year>
<month>12</month>;<volume>38</volume>(<issue>4</issue>):<fpage>963</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.2307/2529876</pub-id><pub-id pub-id-type="pmid">7168798</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Taylor</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Law</surname>
<given-names>N</given-names></string-name>. <article-title>Does the covariance structure matter in longitudinal modelling for the prediction of future CD4 counts?</article-title>
<source>Stat Med</source>. <year>1998</year>
<month>10</month>
<day>30</day>;<volume>17</volume>(<issue>20</issue>):<fpage>2381</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19981030)17:20&#x0003c;2381::AID-SIM926&#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">9819834</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="book"><string-name><surname>Balakrishna</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lai</surname>
<given-names>C</given-names></string-name>. Chapter 11: <chapter-title>Bivariate normal distribution.</chapter-title> In: <string-name><surname>Balakrishna</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lai</surname>
<given-names>C</given-names></string-name>, editors. <source>Continuous bivariate distributions.</source>
<edition>2nd ed.</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2009</year> pp. <fpage>478</fpage>&#x02013;<lpage>561</lpage>.</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Pantazis</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Porter</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Costagliola</surname>
<given-names>D</given-names></string-name>, <string-name><surname>De Luca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ghosn</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guiguet</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study.</article-title>
<source>Lancet HIV.</source>
<year>2014</year>;<volume>1</volume>(<issue>3</issue>):<fpage>e119</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-3018(14)00002-2</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Lodi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Phillips</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Touloumi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Geskus</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Meyer</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Thi&#x000e9;baut</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>; <collab>CASCADE Collaboration in EuroCoord</collab>. <article-title>Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds &#x0003c;200, &#x0003c;350, and &#x0003c;500 Cells/mm3: assessment of need following changes in treatment guidelines.</article-title>
<source>Clin Infect Dis</source>. <year>2011</year>
<month>10</month>;<volume>53</volume>(<issue>8</issue>):<fpage>817</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir494</pub-id><pub-id pub-id-type="pmid">21921225</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Wandel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Egger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rangsin</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Nelson</surname>
<given-names>KE</given-names></string-name>, <string-name><surname>Costello</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lewden</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>; <collab>Eligibility for ART in lower income countries (eART-linc) collaboration</collab>. <article-title>Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies.</article-title>
<source>Sex Transm Infect</source>. <year>2008</year>
<month>8</month>;<volume>84</volume>
<issue>Suppl 1</issue>:<fpage>i31</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/sti.2008.029793</pub-id><pub-id pub-id-type="pmid">18647863</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Ford</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Meintjes</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Pozniak</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bygrave</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hill</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Peter</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>The future role of CD4 cell count for monitoring antiretroviral therapy.</article-title>
<source>Lancet Infect Dis</source>. <year>2015</year>
<month>2</month>;<volume>15</volume>(<issue>2</issue>):<fpage>241</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70896-5</pub-id><pub-id pub-id-type="pmid">25467647</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Hemelaar</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gouws</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ghys</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Osmanov</surname>
<given-names>S</given-names></string-name>; <collab>WHO-UNAIDS Network for HIV Isolation and Characterisation</collab>. <article-title>Global trends in molecular epidemiology of HIV-1 during 2000&#x02013;2007.</article-title>
<source>AIDS</source>. <year>2011</year>
<month>3</month>
<day>13</day>;<volume>25</volume>(<issue>5</issue>):<fpage>679</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e328342ff93</pub-id><pub-id pub-id-type="pmid">21297424</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Lihana</surname>
<given-names>RW</given-names></string-name>, <string-name><surname>Ssemwanga</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Abimiku</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ndembi</surname>
<given-names>N</given-names></string-name>. <article-title>Update on HIV-1 diversity in Africa: a decade in review.</article-title>
<source>AIDS Rev</source>. <year>2012</year>
<season>Apr-Jun</season>;<volume>14</volume>(<issue>2</issue>):<fpage>83</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">22627605</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Laurent</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bourgeois</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Faye</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Mougnutou</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Seydi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gueye</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study.</article-title>
<source>J Infect Dis</source>. <year>2002</year>
<month>8</month>
<day>15</day>;<volume>186</volume>(<issue>4</issue>):<fpage>486</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1086/341833</pub-id><pub-id pub-id-type="pmid">12195375</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Pantazis</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Morrison</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Amornkul</surname>
<given-names>PN</given-names></string-name>, <string-name><surname>Lewden</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Salata</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Minga</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>; <collab>CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group</collab>. <article-title>Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.</article-title>
<source>PLoS ONE</source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e32369</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0032369</pub-id><pub-id pub-id-type="pmid">22412867</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Herbeck</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Maust</surname>
<given-names>BS</given-names></string-name>, <string-name><surname>Ledergerber</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Torti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Di Giambenedetto</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.</article-title>
<source>AIDS</source>. <year>2012</year>
<month>1</month>
<day>14</day>;<volume>26</volume>(<issue>2</issue>):<fpage>193</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32834db418</pub-id><pub-id pub-id-type="pmid">22089381</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Payne</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Muenchhoff</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Roberts</surname>
<given-names>HE</given-names></string-name>, <string-name><surname>Matthews</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Adland</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal>
<article-title>Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence.</article-title>
<source>Proc Natl Acad Sci USA</source>. <year>2014</year>
<month>12</month>
<day>16</day>;<volume>111</volume>(<issue>50</issue>):<fpage>E5393</fpage>&#x02013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1413339111</pub-id><pub-id pub-id-type="pmid">25453107</pub-id></mixed-citation></ref></ref-list></back></article>